Samsung Bioepis Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Subsidiary
- Established
- 2012-01-01
- Employees
- 501
- Market Cap
- -
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 616
- Registration Number
- NCT06348199
- Locations
- 🇹🇷
SB Investigative Site, Sivas, Turkey
A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects with Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 135
- Registration Number
- NCT06268613
- Locations
- 🇹🇷
SB Investigative Site, Istanbul, Turkey
A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT06176963
- Locations
- 🇵🇱
SB Investigational Site, Olsztyn, Poland
Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 371
- Registration Number
- NCT05510063
- Locations
- 🇵🇱
SB Investigative Site, Świdnik, Poland
A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 503
- Registration Number
- NCT04967508
- Locations
- 🇺🇦
SB Investigative Site, Zaporizhzhia, Ukraine
🇪🇪SB investigative site, Tallinn, Estonia
A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to European Union (EU) Sourced Stelara and United States of America (US) Sourced Stelara in Healthy Subjects
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 201
- Registration Number
- NCT04772274
- Locations
- 🇫🇷
Biotrial Rennes, Rennes, France
A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 457
- Registration Number
- NCT04664959
- Locations
- 🇵🇱
SB Investigative Site, Łódź, Poland
Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male Subjects
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT04621318
- Locations
- 🇺🇸
Biotrial, Newark, New Jersey, United States
🇫🇷Biotrial Rennes, Rennes, France
Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male Subjects
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 188
- Registration Number
- NCT04514796
- Locations
- 🇩🇪
Parexel International GmbH, Early Phase Clinical Unit Berlin, Berlin, Germany
A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-06-29
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Samsung Bioepis Co., Ltd.
- Target Recruit Count
- 449
- Registration Number
- NCT04450329
- Locations
- 🇷🇺
SB Investigative Site, Saint Petersburg, Russian Federation
© Copyright 2024. All Rights Reserved by MedPath